Floatz logo

FILGRASTIM

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

National Cancer Institute (NCI)protein_peptidePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Cediranib
University of Southern California
Phase 3BB

View all 28 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →